Amyloid-β (Aβ) PET imaging has now been available for over 15 years. The ability to detect
Aβ in vivo has greatly improved the clinical and research landscape of Alzheimer's disease …

Imaging of brain β-amyloid plaques with 18F-labeled tracers for PET will likely be available
in clinical practice to assist the diagnosis of Alzheimer disease (AD). With the rapidly …

Currently, 3 amyloid PET tracers are approved and commercially available for clinical use.
They allow for the accurate in vivo detection of amyloid plaques, one hallmark of Alzheimer …

Molecular neuroimaging techniques such as PET are proving valuable in the early and
differential diagnosis of Alzheimer's disease (AD). With the advent of new therapeutic …

The devastating effects of the still incurable Alzheimer's disease (AD) project an ever
increasing shadow of burden on the health care system and society in general. In this …

Although diagnosing the syndrome of dementia is largely a clinical endeavor, neuroimaging
plays an increasingly important role in accurately determining the underlying etiology, which …

Although the diagnosis of dementia is still largely a clinical one, based on history and
disease course, neuroimaging has dramatically increased our ability to accurately diagnose …

Alzheimer's disease (AD) is a complex neurodegenerative disorder of which the exact cause
is still not known. There has, however, been remarkable progress in the understanding of …

Amyloid positron emission tomography (PET) imaging enables in vivo detection of brain Aβ
deposition, one of the neuropathological hallmarks of Alzheimer's disease. There is …

With the advent of new therapeutic strategies aimed at reducing β-amyloid (Aβ) burden in
the brain to potentially prevent or delay functional and irreversible cognitive loss, there is …